Clinical Trials Logo

Clinical Trial Summary

This qualitative study is designed to elicit the perspectives of relevant stakeholders to adapt a community-based TB/HIV intervention aimed on providing home-based TB prevention treatment (TPT) initiation for child TB contacts, to design its implementation strategy and, post intervention, to assess lessons learned for future scale up. Participants will include policy makers and health system managers, nurse and physician providers, community health team members, and child caregivers of TB-exposed children. Stakeholders will be asked to participate in two interviews, one prior to the cluster randomized trial assessing this intervention and one after the cluster randomized trial. Trained interviewers will conduct 1-hour semi-structured in-depth interviews that will be audio-recorded, translated and transcribed for thematic analysis using a priori and emergent domains of interest. Free-listing, ranking exercises and cultural consensus will be used to identify context-specific intervention adaptations and implementation strategies.


Clinical Trial Description

Tuberculosis (TB) remains a top 10 cause of child mortality in sub-Saharan Africa. Short-course combination TB preventive therapy (TPT) regimens are highly effective with high completion rates and therefore hold promise to reduce the 1 million pediatric TB patients and 233,000 child TB deaths annually. TPT effectiveness requires improvement in access to pediatric TB preventive care. The World Health Organization (WHO) estimates only 23% of the 1.3 million TB-exposed children under 5 years old initiated TPT in 2017. The investigators' previous data suggest 50-75% of TB-exposed children under 5 years old fail to be either identified or linked to TB preventive care. Children under 5 years are at exceptionally high risk of TB disease due to not only immature immune systems, but also HIV infection and HIV exposure. Guidelines have long recommended TPT for children under 5 years, but have recently been expanded to children under 15 years. Developing and testing innovative health care delivery models to accompany new WHO-endorsed short-course combination TPT regimens is essential to reduce TB-associated global child morbidity and mortality. Integrated community case management (iCCM) is a cost-effective intervention that increases child survival by bringing curative therapies to at risk children in the community. Recently, algorithms for screening pediatric patients with household exposure to TB have been simplified to include symptom screening only, eliminating costly laboratory and radiographic evaluations that are barriers to treatment and do not improve sensitivity and specificity of the assessment. The CHIP-TB Trial plans to assess whether integrated community-based pediatric TB/HIV prevention services is feasible, acceptable and effective in increasing TPT uptake among child TB contacts under 15 years in a cluster-randomized trial in South Africa and Ethiopia, two high-burden, resource-limited settings. Nested within this larger trial, the investigators will use qualitative research to (1) describe the social context in which the community health teams perform the team's duties, (2) make context-specific adaptations to the intervention to maximize its effectiveness, (3) define a context-specific implementation strategy and evaluation plan, and (4) learn important lessons for the future scale up and dissemination of the community-based intervention. The investigators will conduct 10-15 paired semi-structured individual in-depth interviews (IDI) for each of the four key stakeholder groups: (1) caregivers of TB-exposed children, (2) community health team members, (3) clinic-based nurse and clinic or hospital-based physician providers, and (4) health system managers and policy makers, for a total of ~120 IDIs (~60 in South Africa and ~60 in Ethiopia) both pre and post trial. Before the intervention the investigators will conduct a one-hour interview that will explore the inner setting of the community health team's environment from each stakeholder perspective and will develop and decide upon key intervention adaptations and implementation strategies for the community-based TB/HIV prevention program that will be assessed with a one-year cluster-randomized trial. Upon trial completion, the investigators will conduct another 10-15 semi-structured IDIs with each stakeholder group in each country (total ~120 IDIs) to identify key facilitators and barriers to the implementation. Thematic content analysis with an inductive approach will be used to analyze transcripts for both a priori and emergent domains of interest. A coding scheme will be adapted from Consolidated Framework for Implementation Research (CFIR) constructs. Free listing, ranking, and cultural consensus will be used to identify intervention adaptations and implementation strategies that are context specific. The investigators will use Smith's Saliency Index to analyze the free listed data, mean rank order to assess ranking exercises, and the Eigenvalue to evaluate consensus across groups all using the ANTHROPAC ® 4.0 software. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04494516
Study type Observational
Source Johns Hopkins University
Contact
Status Completed
Phase
Start date June 4, 2021
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Completed NCT04545164 - Computer Aided Screening for Tuberculosis in Low Resource Environments N/A
Recruiting NCT05766267 - Short-course Regimens for the Treatment of Pulmonary Tuberculosis Phase 2/Phase 3
Recruiting NCT05756582 - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Enrolling by invitation NCT04988984 - Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
Recruiting NCT04148053 - Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Recruiting NCT01689831 - Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) Phase 2
Completed NCT05945498 - Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years Phase 1
Not yet recruiting NCT06352970 - Effects of Tuberculosis Infection on Development and Function of the Placenta
Recruiting NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Phase 2
Recruiting NCT05413551 - Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention Phase 1
Recruiting NCT03941210 - Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
Withdrawn NCT03265977 - A Phase II Study of H56:IC31 in Healthy Adolescents Phase 2
Recruiting NCT05069688 - Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Phase 1
Suspended NCT05330884 - BCG Revaccination in Children and Adolescents Phase 3
Recruiting NCT05342064 - Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service N/A
Recruiting NCT05236452 - Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection N/A
Recruiting NCT05443178 - Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Phase 1
Recruiting NCT05122026 - Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Phase 1/Phase 2
Recruiting NCT06221488 - Testing Health Workers At Risk to Advance Our Understanding of TB Infection